EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

摘要: PURPOSEBased on in vitro evidence that tumor cells are less resistant to prolonged exposure low concentrations of the natural product class, compared with brief higher concentration exposure, we developed a chemotherapy regimen (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone [EPOCH]) which products administered as continuous infusion.PATIENTS AND METHODSThis is phase II study etoposide, 96-hour infusion, intravenous (IV) bolus cyclophosphamide oral (EPOCH) 74 consecutive patients who relapsed from or failed respond most same drugs schedule. Patients aggressive lymphomas achieved good response after EPOCH were eligible undergo bone marrow transplantation.RESULTSPatients intermediate- high-grade lymphoma comprised 76% this series 77% had stage IV disease. Seventy-one percent previously received all d...